A recent study published in Sleep sheds light on the relationship between caffeine consumption and its impact on sleep.
The addition of atezolizumab to neoadjuvant chemotherapy failed to significantly improve event-free survival in patients with ...
Zacks.com on MSN10d
CORT's Dazucorilant Fails to Meet Goal in Neurologic Disorder StudyCorcept Therapeutics Incorporated CORT announced data from the phase II DAZALS study evaluating its selective cortisol ...
However, the combination of Merck's approved doravirine and investigational islatravir didn't prove superiority over Gilead's ...
The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet ...
Corcept Therapeutics drug Korlym, which treats hypercortisolism and difficult-to-control type 2 diabetes, met its primary endpoint in the treatment phase of CATALYST, a randomized, double-blind, ...
The following is a summary of “Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a ...
The 48-week end points of the MANIFEST-2 study show improvements in spleen reduction, symptoms, bone marrow fibrosis, and ...
III-21," a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of bovhyaluronidase azoximer ...
CervoMed shares collapsed Tuesday after the clinical-stage company reported a mid-stage study failure of its lead program. Shares of the Boston company were recently changing hands at $2.26, down 78%, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback